Similar articles

• Managing adverse effects of interferon-alfa and ribavirin in combination therapy for HCV.

  Slim J, Afridi MS. Slim J, et al. Infect Dis Clin North Am. 2012 Dec;26(4):917-29. doi: 10.1016/j.idc.2012.08.006. Infect Dis Clin North Am. 2012. PMID: 23083824 Review.
• Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin.

  Bronowicki JP, Ouzan D, Asselah T, Desmorat H, Zarski JP, Foucher J, Bourlière M, Renou C, Tran A, Melin P, Hézode C, Chevalier M, Bouvier-Alias M, Chevaliez S, Montestruc F, Lonjon-Domanec I, Pawlotsky JM. Bronowicki JP, et al. Gastroenterology. 2006 Oct;131(4):1040-8. doi: 10.1053/j.gastro.2006.07.022. Epub 2006 Jul 24. Gastroenterology. 2006. PMID: 17030174 Clinical Trial.
• Incidence of neutropenia and infections during combination treatment of chronic hepatitis C with pegylated interferon alfa-2a or alfa-2b plus ribavirin.

  Antonini MG, Babudieri S, Maida I, Baiguera C, Zanini B, Fenu L, Dettori G, Manno D, Mura MS, Carosi G, Puoti M. Antonini MG, et al. Infection. 2008 Jun;36(3):250-5. doi: 10.1007/s15010-007-7132-6. Epub 2008 May 3. Infection. 2008. PMID: 18458815 Clinical Trial.
• Mania during treatment of chronic hepatitis C with pegylated interferon and ribavirin.

  Onyike CU, Bonner JO, Lyketsos CG, Treisman GJ. Onyike CU, et al. Am J Psychiatry. 2004 Mar;161(3):429-35. doi: 10.1176/appi.ajp.161.3.429. Am J Psychiatry. 2004. PMID: 14992966 No abstract available.
• Pegylated interferon-alfa plus ribavirin therapies for chronic hepatitis C.

  Kanda T, Yokosuka O. Kanda T, et al. JNMA J Nepal Med Assoc. 2011 Jan-Mar;51(181):41-8. JNMA J Nepal Med Assoc. 2011. PMID: 22335095 Review.